Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study.

ABSTRACT:

Introduction

Sacituzumab govitecan (SG) is approved for patients with previously treated metastatic or locally advanced triple-negative breast cancer (TNBC), as per the ASCENT trial results. Real-world studies (RWSs) cover more diverse patients than clinical trials, offering crucial data for healthcare policies. This study aimed to investigate the safety and efficacy of SG in real-world Polish patients with previously treated metastatic TNBC.

Methods

In this ambispective multicenter cohort study, we collected demographic and clinical data. Premedication, adjustments in SG dosage, and treatment regimen adhered to the product's characteristics.

Results

We included 79 female patients. The median age at SG initiation was 53 years; 32% of patients were initially diagnosed

SUBMITTER: Puskulluoglu M 

PROVIDER: S-EPMC11573939 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature